FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895065487> ?p ?o ?g. }

• W2895065487 endingPage "e0185111" @default.
• W2895065487 startingPage "e0185111" @default.
• W2895065487 abstract "Previously, Bithionol (BT) was shown to enhance the chemosensitivity of ovarian cancer cell lines to cisplatin treatment. In the present study, we focused on the anti-tumor potential of the BT-paclitaxel combination when added to a panel of ovarian cancer cell lines. This in vitro study aimed to 1) determine the optimum schedule for combination of BT and paclitaxel and 2) assess the nature and mechanism(s) underlying BT-paclitaxel interactions. The cytotoxic effects of both drugs either alone or in combination were assessed by presto-blue cell viability assay using six human ovarian cancer cell lines. Inhibitory concentrations to achieve 50% cell death (IC50) were determined for BT and paclitaxel in each cell line. Changes in levels of cleaved PARP, XIAP, bcl-2, bcl-xL, p21 and p27 were determined via immunoblot. Luminescent and colorimetric assays were used to determine caspases 3/7 and autotaxin (ATX) activity. Cellular reactive oxygen species (ROS) were measured by flow cytometry. Our results show that the efficacy of the BT-paclitaxel combination depends upon the concentrations and sequence of addition of paclitaxel and BT. Pretreatment with BT followed by paclitaxel resulted in antagonistic interactions whereas synergistic interactions were observed when both drugs were added simultaneously or when cells were pretreated with paclitaxel followed by BT. Synergistic interactions between BT and paclitaxel were attributed to increased ROS generation and enhanced apoptosis. Decreased expression of pro-survival factors (XIAP, bcl-2, bcl-xL) and increased expression of pro-apoptotic factors (caspases 3/7, PARP cleavage) was observed. Additionally, increased expression of key cell cycle regulators p21 and p27 was observed. These results show that BT and paclitaxel interacted synergistically at most drug ratios which, however, was highly dependent on the sequence of the addition of drugs. Our results suggest that BT-paclitaxel combination therapy may be effective in sensitizing ovarian cancer cells to paclitaxel treatment, thus mitigating some of the toxic effects associated with high doses of paclitaxel." @default.
• W2895065487 created "2018-10-12" @default.
• W2895065487 creator A5005661299 @default.
• W2895065487 creator A5033198932 @default.
• W2895065487 creator A5041428301 @default.
• W2895065487 creator A5041953211 @default.
• W2895065487 date "2017-09-20" @default.
• W2895065487 modified "2023-09-24" @default.
• W2895065487 title "Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines" @default.
• W2895065487 cites W1574056173 @default.
• W2895065487 cites W1596431542 @default.
• W2895065487 cites W180777263 @default.
• W2895065487 cites W1905538010 @default.
• W2895065487 cites W1942558153 @default.
• W2895065487 cites W1968965382 @default.
• W2895065487 cites W1971967721 @default.
• W2895065487 cites W1972779889 @default.
• W2895065487 cites W1994880455 @default.
• W2895065487 cites W1999304864 @default.
• W2895065487 cites W2000420730 @default.
• W2895065487 cites W2006122393 @default.
• W2895065487 cites W2013470095 @default.
• W2895065487 cites W2022685798 @default.
• W2895065487 cites W2029942210 @default.
• W2895065487 cites W2044789358 @default.
• W2895065487 cites W2048580070 @default.
• W2895065487 cites W2049209075 @default.
• W2895065487 cites W2051398284 @default.
• W2895065487 cites W2056552249 @default.
• W2895065487 cites W2059204272 @default.
• W2895065487 cites W2062808499 @default.
• W2895065487 cites W2067299834 @default.
• W2895065487 cites W2070198605 @default.
• W2895065487 cites W2073838116 @default.
• W2895065487 cites W2076131352 @default.
• W2895065487 cites W2081406767 @default.
• W2895065487 cites W2084042603 @default.
• W2895065487 cites W2096439168 @default.
• W2895065487 cites W2097026238 @default.
• W2895065487 cites W2099473254 @default.
• W2895065487 cites W2101575450 @default.
• W2895065487 cites W2108929767 @default.
• W2895065487 cites W2109637975 @default.
• W2895065487 cites W2113587402 @default.
• W2895065487 cites W2115954319 @default.
• W2895065487 cites W2117398014 @default.
• W2895065487 cites W2118942134 @default.
• W2895065487 cites W2121686752 @default.
• W2895065487 cites W2129074578 @default.
• W2895065487 cites W2142033690 @default.
• W2895065487 cites W2166385797 @default.
• W2895065487 cites W2167978831 @default.
• W2895065487 cites W2171746048 @default.
• W2895065487 cites W2338906686 @default.
• W2895065487 cites W2578968110 @default.
• W2895065487 cites W4255762755 @default.
• W2895065487 doi "https://doi.org/10.1371/journal.pone.0185111" @default.
• W2895065487 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5607185" @default.
• W2895065487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28931042" @default.
• W2895065487 hasPublicationYear "2017" @default.
• W2895065487 type Work @default.
• W2895065487 sameAs 2895065487 @default.
• W2895065487 citedByCount "9" @default.
• W2895065487 countsByYear W28950654872018 @default.
• W2895065487 countsByYear W28950654872019 @default.
• W2895065487 countsByYear W28950654872020 @default.
• W2895065487 countsByYear W28950654872021 @default.
• W2895065487 countsByYear W28950654872023 @default.
• W2895065487 crossrefType "journal-article" @default.
• W2895065487 hasAuthorship W2895065487A5005661299 @default.
• W2895065487 hasAuthorship W2895065487A5033198932 @default.
• W2895065487 hasAuthorship W2895065487A5041428301 @default.
• W2895065487 hasAuthorship W2895065487A5041953211 @default.
• W2895065487 hasBestOaLocation W28950654871 @default.
• W2895065487 hasConcept C109316439 @default.
• W2895065487 hasConcept C121608353 @default.
• W2895065487 hasConcept C153911025 @default.
• W2895065487 hasConcept C185592680 @default.
• W2895065487 hasConcept C190283241 @default.
• W2895065487 hasConcept C202751555 @default.
• W2895065487 hasConcept C2776694085 @default.
• W2895065487 hasConcept C2777292972 @default.
• W2895065487 hasConcept C2778239845 @default.
• W2895065487 hasConcept C2780427987 @default.
• W2895065487 hasConcept C31573885 @default.
• W2895065487 hasConcept C33195913 @default.
• W2895065487 hasConcept C502942594 @default.
• W2895065487 hasConcept C53227056 @default.
• W2895065487 hasConcept C54355233 @default.
• W2895065487 hasConcept C553184892 @default.
• W2895065487 hasConcept C55493867 @default.
• W2895065487 hasConcept C81885089 @default.
• W2895065487 hasConcept C86803240 @default.
• W2895065487 hasConcept C96232424 @default.
• W2895065487 hasConcept C98274493 @default.
• W2895065487 hasConcept C98424977 @default.
• W2895065487 hasConceptScore W2895065487C109316439 @default.
• W2895065487 hasConceptScore W2895065487C121608353 @default.

• next